Caristo Diagnostics is a medical technology company that applies artificial intelligence to cardiac imaging. Founded in 2018 as a spinout from the University of Oxford, the company's work is grounded in over a decade of scientific research by cardiologists, with findings published in leading medical journals. Its core business focuses on quantifying coronary inflammation from routine coronary CT angiography (CCTA) scans.
The company's primary products are the CaRi-Heart technology, which uses AI algorithms to analyze CCTA scans and stratify patients by heart attack risk, and the CaRi-Plaque technology, an AI-based tool for heart disease detection that has received FDA approval in the United States. Caristo operates across the technical domains of artificial intelligence, computer vision, and medical imaging, applying them specifically to cardiology.
Caristo Diagnostics has secured commercial regulatory approvals in the United Kingdom, Europe, and Australia, and has raised over £23 million in venture capital funding. The company maintains a presence in Oxford, across Europe, Australia, and the United States.
